Kymera Therapeutics, Inc.

Contributing Author

Recent Articles by Kymera Therapeutics, Inc.

Jun-25	Kymera Therapeutics Announces Proposed Public Offering KYMR GlobeNewswire
Jun-25	Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update KYMR GlobeNewswire
Jun-02	Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader KYMR GlobeNewswire
May-30	Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 KYMR GlobeNewswire
May-29	Kymera Therapeutics to Participate in Upcoming June Investor Conferences KYMR GlobeNewswire
May-19	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference KYMR GlobeNewswire
May-09	Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases KYMR GlobeNewswire
May-09	Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update KYMR GlobeNewswire
May-07	Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference KYMR GlobeNewswire